デジタル定量吸入器の世界市場:定量及びソフトミスト吸入器、乾燥粉末吸入器

LINEで送る

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Metered dose and soft mist inhalers – Market size and forecast 2018-2023
• Dry powder inhalers – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Rising integration of AI and adoption of IoT
• Business strategies
• Growing internet connectivity and use of smartphone devices
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AstraZeneca Plc
• GlaxoSmithKline Plc
• Novartis AG
• OPKO Health Inc.
• Teva Pharmaceutical Industries Ltd.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Product overview
Exhibit 02: Global medical devices market
Exhibit 03: Segments of global medical devices market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Hospital admission rate for asthma and COPD in adults in 2015 per 100,000 population
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition – Five forces 2018
Exhibit 19: Product – Market share 2018-2023 (%)
Exhibit 20: Comparison by product
Exhibit 21: Metered dose and soft mist inhalers – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Metered dose and soft mist inhalers – Year-over-year growth 2019-2023 (%)
Exhibit 23: Dry powder inhalers – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Dry powder inhalers – Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by product
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America – Year-over-year growth 2019-2023 (%)
Exhibit 31: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 33: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 35: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Percentage of population with self-reported COPD aged 15 and over in 2014 (Europe)
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: AstraZeneca Plc – Vendor overview
Exhibit 47: AstraZeneca Plc – Product segments
Exhibit 48: AstraZeneca Plc – Organizational developments
Exhibit 49: AstraZeneca Plc – Geographic focus
Exhibit 50: AstraZeneca Plc – Segment focus
Exhibit 51: AstraZeneca Plc – Key offerings
Exhibit 52: AstraZeneca Plc – Key customers
Exhibit 53: GlaxoSmithKline Plc – Vendor overview
Exhibit 54: GlaxoSmithKline Plc – Business segments
Exhibit 55: GlaxoSmithKline Plc – Organizational developments
Exhibit 56: GlaxoSmithKline Plc – Geographic focus
Exhibit 57: GlaxoSmithKline Plc – Segment focus
Exhibit 58: GlaxoSmithKline Plc – Key offerings
Exhibit 59: GlaxoSmithKline Plc – Key customers
Exhibit 60: Novartis AG – Vendor overview
Exhibit 61: Novartis AG – Business segments
Exhibit 62: Novartis AG – Organizational developments
Exhibit 63: Novartis AG – Geographic focus
Exhibit 64: Novartis AG – Segment focus
Exhibit 65: Novartis AG – Key offerings
Exhibit 66: Novartis AG – Key customers
Exhibit 67: OPKO Health Inc. – Vendor overview
Exhibit 68: OPKO Health Inc. – Business segments
Exhibit 69: OPKO Health Inc. – Organizational developments
Exhibit 70: OPKO Health Inc. – Geographic focus
Exhibit 71: OPKO Health Inc. – Key offerings
Exhibit 72: OPKO Health Inc. – Key customers
Exhibit 73: Teva Pharmaceutical Industries Ltd. – Vendor overview
Exhibit 74: Teva Pharmaceutical Industries Ltd. – Business segments
Exhibit 75: Teva Pharmaceutical Industries Ltd. – Organizational developments
Exhibit 76: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibit 77: Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibit 78: Teva Pharmaceutical Industries Ltd. – Key customers
Exhibit 79: Validation techniques employed for market sizing
Exhibit 80: Definition of market positioning of vendors




※当サイトのレポート紹介カバレッジ
■産業:医療、IT、電子、自動車、産業機械、建設、消費財、食品、化学、材料、エネルギー、金融、サービスなど多様
■地域:世界市場、アジア市場、中国市場、欧州市場、北米市場、中南米市場、中東市場、アフリカ市場など全世界
■レポート種類:市場動向、規模、占有率、トレンド、将来展望、未来予測、業界分析、産業分析、企業分析、事業機会分析、戦略提言など多様